An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures

Trial Profile

An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Apr 2017

At a glance

  • Drugs Retigabine (Primary) ; Antiepileptic drugs
  • Indications Partial epilepsies
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 09 Apr 2017 Status changed from recruiting to completed.
    • 28 Sep 2016 Planned End Date changed from 1 Feb 2019 to 1 Nov 2025.
    • 28 Sep 2016 Planned primary completion date changed from 1 Feb 2019 to 1 Nov 2025.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top